Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

1. Clinical Overview

Summary

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), represents the hepatic manifestation of metabolic syndrome and is now the leading cause of chronic liver disease worldwide. [1] The condition is characterised by excessive hepatic fat accumulation (> 5% of hepatocytes) in the absence of significant alcohol consumption or other secondary causes of steatosis. [2]

The global prevalence of MASLD is estimated at 25-30% of the general adult population, with significantly higher rates in individuals with obesity (70-90%) and type 2 diabetes mellitus (55-70%). [3] The disease spectrum ranges from simple steatosis (fat accumulation alone) to Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly NASH), characterised by hepatocellular injury, inflammation, and progressive fibrosis. Approximately 20-30% of patients with simple steatosis will progress to MASH, and up to 20% of those with MASH will develop cirrhosis over 10-20 years. [4]

The condition carries substantial morbidity and mortality, though notably, cardiovascular disease remains the leading cause of death in MASLD patients, exceeding liver-related mortality. [5] This underscores the critical importance of comprehensive metabolic risk factor management in addition to liver-directed therapy.

The 2023 Nomenclature Change

In June 2023, a multi-society Delphi consensus introduced new nomenclature to replace NAFLD/NASH terminology. [1] The change addresses several limitations of the previous framework:

Key Terminology Updates:

• NAFLD → MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
• NASH → MASH (Metabolic Dysfunction-Associated Steatohepatitis)
• New category: MetALD (MASLD with moderate alcohol intake)

Rationale for Change:

1. Removes stigmatising language associated with "fatty" and negative definition of "non-alcoholic"
2. Emphasises positive inclusion criteria based on cardiometabolic risk factors
3. Acknowledges the common overlap between metabolic and alcohol-related liver disease
4. Aligns nomenclature with pathophysiology (metabolic dysfunction as primary driver)

Diagnostic Criteria for MASLD:

• Evidence of hepatic steatosis (imaging or histology) AND
• Presence of at least one of five cardiometabolic risk factors:
  1. BMI ≥25 kg/m² (≥23 kg/m² in Asian populations) or waist circumference > 94 cm (men) or > 80 cm (women)
  2. Fasting glucose ≥5.6 mmol/L or 2-hour post-load glucose ≥7.8 mmol/L or HbA1c ≥39 mmol/mol or type 2 diabetes or treatment for diabetes
  3. Blood pressure ≥130/85 mmHg or antihypertensive treatment
  4. Plasma triglycerides ≥1.7 mmol/L or lipid-lowering treatment
  5. Plasma HDL-cholesterol less than 1.0 mmol/L (men) or less than 1.3 mmol/L (women) or lipid-lowering treatment

Clinical Pearls

Cardiovascular Risk Supersedes Liver Risk: The most common cause of death in MASLD patients is cardiovascular disease (myocardial infarction, stroke), not liver failure. [5] Management must prioritise aggressive cardiovascular risk reduction including statins, blood pressure control, and antiplatelet therapy where indicated. Statins are safe in MASLD and should not be withheld due to elevated transaminases.

Normal Transaminases Do Not Exclude Disease: Up to 50% of patients with biopsy-proven MASH and advanced fibrosis have normal ALT and AST levels. [6] Relying solely on liver function tests will miss significant disease. Non-invasive fibrosis risk stratification (FIB-4, elastography) is mandatory for all at-risk populations, regardless of transaminase levels.

Fibrosis Stage Determines Prognosis: The single most important predictor of liver-related and all-cause mortality is the degree of hepatic fibrosis, not the presence or severity of steatosis or inflammation. [7] Patients with F0-F2 fibrosis have similar mortality to the general population, while F3-F4 fibrosis confers significantly increased risk. Clinical management should focus on identifying and monitoring those with advanced fibrosis.

---

2. Epidemiology

Global Prevalence

MASLD is now recognised as the most common chronic liver disease globally, with estimated prevalence of 25-30% in the general adult population. [3] However, prevalence varies significantly by geography, ethnicity, and the presence of metabolic risk factors.

Demographics

Age: Prevalence increases with age, peaking in the 5th-6th decades. However, MASLD is increasingly diagnosed in children and adolescents, paralleling rising obesity rates. Paediatric MASLD affects 3-10% of children globally and up to 34% of obese children. [12]

Sex: Historical studies suggested higher prevalence in men, but recent data indicate similar rates in postmenopausal women. Premenopausal women appear relatively protected, suggesting a role for oestrogen in hepatic lipid metabolism. [13]

Ethnicity: Significant ethnic variation exists, largely explained by genetic polymorphisms:

• Highest prevalence: Hispanic/Latino populations (23-45%), particularly Mexican Americans
• Moderate prevalence: Caucasian populations (15-25%)
• Lower prevalence: African/African American populations (13-14%)
• Asian populations: Lower BMI threshold for risk (≥23 kg/m²), with "lean MASLD" more common

These differences are partly explained by the PNPLA3 I148M variant (increased risk) which is more prevalent in Hispanic populations, and the TM6SF2 E167K variant. Conversely, African populations have higher frequencies of protective variants. [14]

Disease Progression Rates

Risk Factors

Primary Metabolic Risk Factors (see MASLD diagnostic criteria above):

1. Obesity and central adiposity
2. Type 2 diabetes mellitus and insulin resistance
3. Dyslipidaemia (high triglycerides, low HDL)
4. Hypertension

Genetic Risk Factors:

• PNPLA3 (I148M): Most significant genetic risk factor; increases steatosis, inflammation, fibrosis, and HCC risk [14]
• TM6SF2 (E167K): Increases steatosis and fibrosis but paradoxically reduces cardiovascular risk
• GCKR: Affects glucose and lipid metabolism
• MBOAT7: Associated with increased fibrosis progression

Secondary Risk Factors:

• Diet high in fructose, saturated fat, and processed foods
• Sedentary lifestyle
• Polycystic ovary syndrome (PCOS)
• Hypothyroidism
• Obstructive sleep apnoea
• Hypopituitarism
• Lipodystrophy syndromes

---

3. Aetiology and Pathophysiology

Primary Aetiology: Insulin Resistance and Metabolic Dysfunction

The fundamental driver of MASLD is insulin resistance, which initiates a cascade of metabolic derangements leading to hepatic steatosis. The pathophysiology is best understood through the sequential "multiple hit" hypothesis.

The Pathogenesis of Hepatic Steatosis (First Hit)

1. Peripheral Insulin Resistance

• Muscle and adipose tissue become resistant to insulin signalling
• Glucose uptake is impaired, leading to hyperglycaemia
• Compensatory hyperinsulinaemia develops
• Insulin's normal suppression of lipolysis is lost

2. Increased Free Fatty Acid Flux

• Uninhibited lipolysis in adipose tissue releases massive amounts of free fatty acids (FFAs) into circulation
• FFAs are taken up by hepatocytes via CD36 and fatty acid transport proteins
• Approximately 60% of hepatic triglyceride in MASLD originates from adipose tissue lipolysis [18]

3. De Novo Lipogenesis (DNL)

• Hyperinsulinaemia activates sterol regulatory element-binding protein-1c (SREBP-1c)
• SREBP-1c upregulates lipogenic enzymes: acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS)
• Dietary carbohydrates, especially fructose, are converted to fatty acids
• Fructose metabolism bypasses key regulatory steps, making it uniquely lipogenic
• DNL contributes approximately 25% of hepatic triglyceride [18]

4. Impaired Fatty Acid Oxidation

• Mitochondrial β-oxidation becomes overwhelmed by substrate excess
• Peroxisomal oxidation is upregulated but produces reactive oxygen species (ROS)
• Microsomal ω-oxidation further increases oxidative stress

5. Decreased VLDL Export

• Hepatocytes attempt to export triglycerides as very-low-density lipoprotein (VLDL)
• VLDL synthesis is limited by apolipoprotein B100 (ApoB100) availability
• Rate of triglyceride synthesis exceeds VLDL export capacity
• Net result: Triglyceride accumulation in hepatocyte cytoplasm as lipid droplets (steatosis)

Exam Detail: ### Molecular Mechanisms of Progression to MASH (Multiple Hits)

Simple steatosis is relatively benign, but additional "hits" trigger the inflammatory and fibrotic cascade characteristic of MASH.

Lipotoxicity

• Not all lipids are equally harmful; specific lipid species are toxic to hepatocytes
• Ceramides: Sphingolipids that induce apoptosis and insulin resistance via activation of protein phosphatase 2A and inhibition of Akt signalling
• Diacylglycerols (DAGs): Activate protein kinase C epsilon (PKCε), which phosphorylates and inhibits insulin receptor signalling
• Free cholesterol: Accumulates in hepatocytes and Kupffer cells, triggering ER stress and inflammasome activation
• Lysophosphatidylcholine: Membrane toxic lipid that disrupts cellular integrity

Oxidative Stress and Mitochondrial Dysfunction

• Overloaded mitochondria produce excessive reactive oxygen species (ROS)
• ROS cause lipid peroxidation, protein oxidation, and DNA damage
• Mitochondrial DNA mutations accumulate, further impairing oxidative capacity
• Uncoupling of oxidative phosphorylation reduces ATP production
• Opening of mitochondrial permeability transition pore triggers apoptosis

Endoplasmic Reticulum Stress

• Excessive lipid and protein synthesis overwhelm ER capacity
• Unfolded protein response (UPR) is chronically activated
• Prolonged UPR activation triggers inflammatory signalling (JNK, NF-κB) and apoptosis (CHOP pathway)
• ER stress also impairs insulin signalling, creating a vicious cycle

Innate Immune Activation

• Damaged hepatocytes release damage-associated molecular patterns (DAMPs)
• Gut-derived lipopolysaccharide (LPS) reaches the liver due to increased intestinal permeability
• Pattern recognition receptors (TLRs, especially TLR4) on Kupffer cells are activated
• Kupffer cells release pro-inflammatory cytokines: TNF-α, IL-1β, IL-6
• NLRP3 inflammasome activation in response to cholesterol crystals amplifies IL-1β production

Hepatocyte Death

• Multiple forms of cell death occur: apoptosis, necroptosis, pyroptosis
• Hepatocyte ballooning (cytoplasmic swelling) is the histological hallmark
• Cytokeratin 18 fragments (M30, M65) are released as biomarkers of apoptosis
• Cell death releases further DAMPs, perpetuating inflammation

Fibrogenesis

• Hepatic stellate cells (HSCs) are normally quiescent, lipid-storing cells in the space of Disse
• HSC activation is triggered by: hepatocyte apoptotic bodies, TGF-β, platelet-derived growth factor (PDGF), ROS, and angiotensin II
• Activated HSCs trans-differentiate into myofibroblasts
• Myofibroblasts produce excessive extracellular matrix (collagen I, III, IV)
• Fibrosis progresses: perisinusoidal (F1) → periportal (F2) → bridging (F3) → cirrhosis (F4)
• Advanced fibrosis is potentially reversible with sufficient metabolic improvement, but cirrhosis represents a largely irreversible threshold

The Gut-Liver Axis

• Obesity and metabolic syndrome alter gut microbiota composition (dysbiosis)
• Reduced bacterial diversity and increased Firmicutes:Bacteroidetes ratio
• Dysbiosis increases intestinal permeability ("leaky gut")
• Bacterial products (LPS, peptidoglycan) reach the liver via portal circulation
• Portal LPS activates hepatic TLR4 signalling, driving inflammation
• Dysbiosis also affects bile acid metabolism and production of beneficial metabolites (e.g., butyrate)

Genetic Susceptibility

PNPLA3 (patatin-like phospholipase domain-containing protein 3):

• The I148M variant is the most robustly associated genetic polymorphism
• Encodes adiponutrin, a lipase expressed on hepatocyte lipid droplets
• The variant impairs triglyceride hydrolysis and promotes lipid accumulation
• Increases risk of steatosis, MASH, fibrosis, cirrhosis, and HCC
• Allele frequency: 49% in Hispanics, 23% in Europeans, 17% in African Americans [14]

TM6SF2 (transmembrane 6 superfamily member 2):

• The E167K variant impairs VLDL secretion
• Increases hepatic steatosis and fibrosis risk
• Paradoxically decreases serum lipids and may reduce cardiovascular disease risk

---

4. Differential Diagnosis

The finding of hepatic steatosis on imaging or elevated transaminases requires systematic exclusion of secondary causes before attributing disease to metabolic dysfunction.

Screening for Secondary Causes

Recommended "Liver Screen" for New Diagnosis of Steatosis:

• Viral serology: Hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV) with reflex RNA if positive
• Autoimmune markers: Antinuclear antibody (ANA), smooth muscle antibody (ASMA), anti-liver-kidney microsomal antibody (anti-LKM1), immunoglobulins
• Iron studies: Serum ferritin, transferrin saturation (if > 45%, consider HFE genotyping)
• Copper studies (if age less than 40): Ceruloplasmin, 24-hour urinary copper
• Alpha-1 antitrypsin level and phenotype (especially if family history or emphysema)
• Coeliac serology: Anti-tissue transglutaminase IgA, total IgA
• Thyroid function: TSH, free T4 (hypothyroidism can cause steatosis and dyslipidaemia)

---

5. Clinical Presentation

Symptoms

Asymptomatic (Majority)

• 80-90% of patients with MASLD are asymptomatic at diagnosis [2]
• Detection is typically incidental during:
  • Routine blood tests showing elevated transaminases
  • Abdominal imaging for unrelated indications
  • Screening in high-risk populations (diabetes, obesity)

Fatigue

• Most common symptom when present (reported in up to 50% of MASLD patients)
• Often disproportionate to liver disease severity
• May be multifactorial: metabolic syndrome, sleep apnoea, depression, hypothyroidism
• Poor correlation with histological disease activity or fibrosis stage

Right Upper Quadrant Discomfort

• Vague, non-specific discomfort or fullness
• Results from hepatomegaly stretching Glisson's capsule
• Not associated with meals (distinguishes from biliary pain)
• Does not predict disease severity

Symptoms of Advanced Disease/Cirrhosis (Late)

• Increasing fatigue and weakness
• Abdominal distension (ascites)
• Peripheral oedema
• Easy bruising (coagulopathy)
• Confusion or personality change (hepatic encephalopathy)
• Haematemesis or melaena (variceal bleeding)
• Jaundice (advanced decompensation)
• Pruritus (cholestasis)

Signs

Early/Simple Steatosis

• Hepatomegaly: Smooth, non-tender liver edge palpable 2-4 cm below costal margin
  • Sensitivity decreases with increasing BMI/abdominal adiposity
  • May be absent despite significant steatosis
• Stigmata of Metabolic Syndrome:
  • Central obesity (increased waist circumference)
  • Acanthosis nigricans (velvety hyperpigmentation in axillae, neck, groin) – marker of insulin resistance
  • Skin tags (acrochordon) – associated with insulin resistance
  • Xanthelasma (eyelid cholesterol deposits) – dyslipidaemia

Signs of Advanced Fibrosis/Cirrhosis

• Cutaneous stigmata:
  • Spider naevi (> 5 is significant; upper body distribution)
  • Palmar erythema
  • Leukonychia (white nails)
  • Clubbing (rare)
  • Dupuytren's contracture
• Abdominal signs:
  • Ascites (shifting dullness, fluid thrill)
  • Splenomegaly (portal hypertension)
  • Caput medusae (dilated periumbilical veins)
  • Hepatomegaly (initially enlarged, then shrinks in advanced cirrhosis)
• Systemic signs:
  • Jaundice (scleral icterus, generalised)
  • Muscle wasting (temporal, proximal limbs)
  • Gynaecomastia and testicular atrophy (men) – altered oestrogen metabolism
  • Loss of body hair
• Neurological signs:
  • Asterixis (hepatic flap) – hepatic encephalopathy
  • Confusion, drowsiness – graded by West Haven criteria

Examination Approach

Exam Detail: Systematic Examination for MASLD Patient:

1. General Inspection: Body habitus (central obesity), muscle wasting, jaundice, skin changes
2. Hands: Palmar erythema, Dupuytren's, clubbing, leukonychia, asterixis
3. Face and Neck: Scleral icterus, xanthelasma, parotid enlargement
4. Chest: Spider naevi (count and document), gynaecomastia, sparse body hair
5. Abdomen:
   • Inspection: Distension, caput medusae, surgical scars
   • Palpation: Liver (size, edge, texture, tenderness, pulsatile?), spleen, kidneys, masses
   • Percussion: Ascites (shifting dullness), liver span
   • Auscultation: Venous hum (portal hypertension), hepatic bruit (HCC)
6. Legs: Peripheral oedema, muscle wasting, acanthosis (groin)
7. Neurological: Mental state (encephalopathy grade), asterixis

Red Flags on Examination (Prompt immediate specialist referral):

• Jaundice with coagulopathy (synthetic dysfunction)
• Ascites (decompensated cirrhosis)
• Confusion or asterixis (hepatic encephalopathy)
• Splenomegaly with thrombocytopenia (portal hypertension)
• Hard, irregular hepatomegaly (consider HCC)

---

6. Investigations

The diagnostic and risk stratification pathway for MASLD involves three sequential steps: (1) detection of steatosis, (2) exclusion of alternative aetiologies, and (3) non-invasive fibrosis risk stratification.

Step 1: Detection of Hepatic Steatosis

Ultrasound Abdomen (First-line imaging)

• Findings in steatosis:
  • Increased hepatic echogenicity ("bright liver")
  • Hepatorenal contrast (liver brighter than kidney)
  • Posterior attenuation of ultrasound beam
  • Vascular blurring (poor visualisation of portal and hepatic veins)
• Advantages: Widely available, inexpensive, no radiation
• Limitations:
  • Qualitative assessment (cannot quantify fat percentage accurately)
  • Sensitivity reduced in obesity (BMI > 40 kg/m²)
  • Cannot detect less than 20% steatosis reliably
  • Operator-dependent

Controlled Attenuation Parameter (CAP)

• Measured simultaneously with transient elastography (FibroScan)
• Quantifies hepatic steatosis (dB/m)
• Thresholds:
  • "S0 (none): less than 248 dB/m"
  • "S1 (mild, 5-33%): 248-267 dB/m"
  • "S2 (moderate, 34-66%): 268-280 dB/m"
  • "S3 (severe, > 66%): > 280 dB/m"
• Advantages: Objective, quantitative, validated against biopsy
• Limitations: Less reliable in severe obesity, ascites; device availability

Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

• Most accurate non-invasive method for quantifying hepatic fat
• Provides percentage of fat in liver tissue
• Threshold: > 5.6% defines steatosis
• Advantages: Highly accurate, reproducible, whole-liver assessment
• Limitations: Expensive, limited availability, not routinely required for diagnosis

Step 2: Exclusion of Secondary Causes

See "Liver Screen" detailed in Differential Diagnosis section above.

Step 3: Non-Invasive Fibrosis Risk Stratification

This is the CRITICAL step that determines prognosis and management pathway. Fibrosis stage, not steatosis severity, predicts outcomes.

A. FIB-4 Index (First-line risk stratification)

Formula: FIB-4 = (Age × AST) / (Platelets × √ALT)

Interpretation (validated in large cohorts):

• less than 1.30: Low risk of advanced fibrosis (F3-F4)
  • Negative predictive value ~90%
  • Manage in primary care with metabolic optimization
  • Repeat FIB-4 annually
• 1.30-2.67: Indeterminate risk
  • Requires second-line assessment (ELF or elastography)
  • ~30% will have advanced fibrosis
• > 2.67: High risk of advanced fibrosis
  • Refer to hepatology
  • Consider second-line testing to confirm
• Age-adjusted threshold for > 65 years: Use > 2.0 as low-risk cut-off (improved specificity)

Advantages: Simple, uses routine blood tests, validated, cost-free, no specialist equipment

Limitations:

• Lower accuracy in age extremes (less than 35 or > 65 years)
• Affected by haemolysis (falsely elevated AST)
• Cannot distinguish F0 vs F1 vs F2 (grey zone is large)
• Less accurate in the presence of diabetes

Exam Detail: FIB-4 Exam Tip: FIB-4 uses Age, AST, ALT, and Platelets. Do NOT confuse with NAFLD Fibrosis Score (NFS), which includes BMI, diabetes, albumin, and AST/ALT ratio. FIB-4 is simpler and preferred in most guidelines as the first-line tool.

B. NAFLD Fibrosis Score (NFS) (Alternative first-line score)

Formula: -1.675 + 0.037 × age + 0.094 × BMI + 1.13 × IFG/diabetes + 0.99 × AST/ALT ratio - 0.013 × platelet count - 0.66 × albumin

Interpretation:

• -1.455 or less: Low risk of advanced fibrosis (NPV 93%)
• > 0.676: High risk of advanced fibrosis (PPV 82%)
• -1.455 to 0.676: Indeterminate

Advantages: Extensively validated, good negative predictive value

Limitations: More complex calculation; requires online calculator; includes BMI which may confound in severe obesity

C. Enhanced Liver Fibrosis (ELF) Test (Second-line blood test)

Components: Measures three serum biomarkers:

1. Hyaluronic acid (HA)
2. Procollagen III N-terminal peptide (PIIINP)
3. Tissue inhibitor of metalloproteinase 1 (TIMP-1)

Interpretation:

• less than 9.8: Low risk of advanced fibrosis
• 9.8-11.3: Indeterminate
• > 11.3: High likelihood of advanced fibrosis
• Threshold for NICE guidance: ≥10.51 suggests advanced fibrosis warranting specialist referral

Advantages: Direct markers of fibrogenesis; not affected by age, BMI, or diabetes

Limitations: Cost; requires specialist laboratory; availability limited in some regions

D. Transient Elastography (FibroScan) (Second-line imaging)

Non-invasive measurement of liver stiffness using ultrasound-based shear wave propagation.

Measurement: Liver Stiffness Measurement (LSM) in kilopascals (kPa)

Interpretation (European Association for the Study of the Liver thresholds):

• less than 8 kPa: Low probability of advanced fibrosis (F0-F2)
• 8-12 kPa: Indeterminate (may be F2 or F3)
• > 12 kPa: High probability of advanced fibrosis (F3-F4)
• > 15-20 kPa: Probable cirrhosis (F4)

Advantages:

• Rapid (less than 10 minutes), painless, outpatient
• Provides steatosis (CAP) and fibrosis (LSM) simultaneously
• Extensively validated
• Intermediate reproducibility (IQR/median less than 30% considered reliable)

Limitations:

• Less accurate in severe obesity (BMI > 35); XL probe improves performance
• Ascites prevents measurement
• Inflammation (elevated ALT) can transiently elevate LSM
• Operator-dependent; requires training
• Cannot reliably distinguish F0 from F1 or F2 from F3

Factors That Increase LSM (Without Fibrosis):

• Active inflammation (elevated ALT/AST)
• Cholestasis
• Hepatic congestion (right heart failure)
• Recent food intake
• Acute hepatitis

E. Magnetic Resonance Elastography (MRE) (Third-line imaging)

Uses MRI with mechanical vibrations to map liver stiffness.

Advantages:

• Most accurate non-invasive method for fibrosis assessment
• Superior to FibroScan in obesity and ascites
• Can image entire liver

Limitations:

• Expensive
• Limited availability
• Not widely accessible outside specialist centres
• Time-consuming

F. Liver Biopsy (Gold Standard for Diagnosis, Not Routine)

Percutaneous or transjugular liver biopsy remains the reference standard for diagnosing MASH and staging fibrosis, but is reserved for specific indications due to invasiveness.

Indications for Biopsy:

1. Diagnosis uncertain despite non-invasive tests
2. Suspected coexistent liver disease (e.g., autoimmune hepatitis, haemochromatosis)
3. Eligibility assessment for clinical trials
4. Medico-legal documentation
5. Discordant non-invasive tests

Histological Features:

MASH Diagnosis Requires All Three:

1. Steatosis: > 5% of hepatocytes
2. Inflammation: Lobular inflammation (mixed inflammatory infiltrate)
3. Ballooning: Hepatocyte ballooning degeneration (swollen cells with rarefied cytoplasm)

Fibrosis Staging (Kleiner/Brunt System):

• F0: No fibrosis
• F1: Perisinusoidal or periportal fibrosis (zone 3)
• F2: Perisinusoidal and portal/periportal fibrosis
• F3: Bridging fibrosis
• F4: Cirrhosis

NAFLD Activity Score (NAS):

• Sum of steatosis (0-3) + inflammation (0-3) + ballooning (0-2)
• NAS 0-2: Not MASH
• NAS 3-4: Borderline
• NAS ≥5: MASH
• Important: NAS is a scoring system for research; MASH diagnosis is categorical (present or absent), not based solely on NAS threshold

Limitations of Biopsy:

• Invasive (risk of bleeding ~0.5%, mortality ~0.01%)
• Sampling error (biopsy represents only 1/50,000th of liver)
• Interobserver variability in interpretation
• Requires adequate sample (≥15 mm length, ≥11 portal tracts)
• Cost and patient reluctance

Recommended Diagnostic Algorithm

                  SUSPECTED MASLD
         (Steatosis on imaging OR elevated ALT
          in patient with metabolic risk factors)
                         ↓
              CONFIRM STEATOSIS
        (Ultrasound or CAP if available)
                         ↓
              EXCLUDE OTHER CAUSES
              (Liver screen bloods)
                         ↓
            CARDIOMETABOLIC RISK FACTORS?
      (≥1 of: obesity, diabetes, HTN, dyslipidaemia)
                    YES ↓ NO → Not MASLD
                         ↓
            **MASLD DIAGNOSIS CONFIRMED**
                         ↓
              CALCULATE FIB-4 SCORE
         ┌───────────┴───────────┐
      less than 1.30                   ≥1.30
  (LOW RISK)            (INDETERMINATE/HIGH)
         ↓                         ↓
  PRIMARY CARE            SECOND-LINE TEST
  MANAGEMENT              (ELF or FibroScan)
  - Lifestyle                     ↓
  - Treat CVD risk        ┌───────┴────────┐
  - Repeat FIB-4        LOW RISK      HIGH RISK
    annually           (ELF less than 9.8,    (ELF ≥9.8,
                       LSM less than 8)       LSM ≥8)
                           ↓               ↓
                   PRIMARY CARE    **REFER HEPATOLOGY**
                   MANAGEMENT      - Advanced fibrosis
                                   - Consider biopsy
                                   - Trial eligibility
                                   - HCC surveillance

---

7. Classification and Staging

Disease Spectrum

MASLD encompasses a spectrum of histological severity:

Fibrosis Staging Systems

Kleiner/Brunt Staging (Most commonly used for MASLD):

• Stage 0: No fibrosis
• Stage 1: Perisinusoidal or periportal fibrosis (zone 3, centrilobular)
  • 1 a: Mild zone 3 perisinusoidal
  • 1 b: Moderate zone 3 perisinusoidal
  • 1 c: Portal/periportal only
• Stage 2: Perisinusoidal and portal/periportal fibrosis
• Stage 3: Bridging fibrosis
• Stage 4: Cirrhosis

Prognostic Significance:

• F0-F1: Mortality similar to general population
• F2: Slight increase in liver-related events; monitor
• F3: Significant increase in liver-related and all-cause mortality
• F4: Cirrhosis – requires HCC surveillance and variceal screening

NAFLD Activity Score (NAS)

Used primarily in clinical trials to quantify disease activity:

Total NAS: Sum of three components (range 0-8)

• 0-2: Steatosis without MASH
• 3-4: Borderline MASH
• ≥5: Definite MASH

Important: MASH is a categorical diagnosis requiring all three features (steatosis, inflammation, ballooning). NAS is a semi-quantitative tool for research, not diagnostic in isolation.

---

8. Management

Management of MASLD is multi-faceted, targeting metabolic risk factors, hepatic inflammation and fibrosis, and cardiovascular disease prevention. No pharmacotherapy is currently licenced specifically for MASLD in most jurisdictions, though several agents show promise.

General Principles

1. Risk stratify by fibrosis stage: Determines intensity of monitoring and treatment
2. Cardiovascular risk is paramount: Statins, antihypertensives, and antiplatelet agents should NOT be withheld
3. Weight loss is cornerstone: Only intervention proven to reverse fibrosis
4. Treat metabolic comorbidities aggressively: Diabetes, hypertension, dyslipidaemia
5. Avoid hepatotoxins: Alcohol should be minimised or eliminated; avoid unnecessary medications

Lifestyle Modification (First-line for All)

Weight Loss – The only intervention consistently shown to reverse steatosis, inflammation, AND fibrosis. [19]

Practical Recommendations:

• Target: 7-10% weight reduction over 6-12 months
• Gradual reduction (0.5-1 kg/week) is sustainable and effective
• Combination of dietary modification and increased physical activity
• Behavioural support improves adherence

Dietary Modification:

• Mediterranean diet: Most evidence; reduces steatosis and improves metabolic parameters [20]
  • High in vegetables, fruits, legumes, whole grains, olive oil, nuts, fish
  • Low in red meat, processed foods, refined sugars
• Reduce fructose intake: Fructose is uniquely lipogenic; avoid sugar-sweetened beverages, high-fructose corn syrup
• Limit saturated fat and processed foods
• Coffee consumption: 2-3 cups/day associated with reduced fibrosis (caffeine and polyphenols may be protective) [21]

Physical Activity:

• Aerobic exercise: 150-200 minutes/week of moderate intensity (e.g., brisk walking, cycling)
  • Reduces hepatic steatosis even without weight loss
  • Improves insulin sensitivity
• Resistance training: 2-3 sessions/week
  • Increases muscle mass, improves insulin sensitivity
• Combined aerobic + resistance: Synergistic benefit

Alcohol:

• Synergistic hepatotoxicity with metabolic dysfunction
• Recommendation: Abstinence or minimal consumption (less than 14 units/week, spread over ≥3 days)
• Moderate alcohol + metabolic syndrome = MetALD (worse prognosis than either alone)

Pharmacotherapy

A. Agents Targeting Hepatic Pathophysiology

1. Vitamin E (α-tocopherol)

• Mechanism: Antioxidant; reduces oxidative stress and lipid peroxidation
• Evidence: PIVENS trial showed histological improvement in MASH resolution and reduced hepatocyte ballooning (but not fibrosis) in non-diabetic adults [22]
• Dose: 800 IU/day
• Indications: Non-diabetic adults with biopsy-proven MASH
• Limitations:
  • Not effective in diabetics (PIVENS exclusion)
  • No benefit for fibrosis
  • "Safety concerns: Meta-analyses suggest increased all-cause mortality and haemorrhagic stroke risk at high doses; possible increased prostate cancer risk in men"
• Guideline status: AASLD/EASL suggest "may be considered" in select non-diabetic MASH patients; not first-line

2. Pioglitazone

• Mechanism: Peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist; improves insulin sensitivity, reduces inflammation, modulates adipokine secretion
• Evidence:
  • "PIVENS trial: Improved histological features of MASH (though did not reach primary endpoint) [22]"
  • "Meta-analyses: Significant improvement in steatosis, inflammation, ballooning, and fibrosis in diabetic and non-diabetic patients"
• Dose: 30-45 mg once daily
• Indications: Biopsy-proven MASH, with or without diabetes
• Advantages: Benefits both MASH histology AND glycaemic control in diabetics
• Limitations:
  • Weight gain (average 2-5 kg)
  • Fluid retention/peripheral oedema
  • "Contraindications: Heart failure (risk of exacerbation), osteoporosis (increased fracture risk in women), bladder cancer"
• Guideline status: AASLD/EASL suggest "may be considered" in biopsy-proven MASH; closer to routine use than Vitamin E in diabetics

3. Resmetirom (MGL-3196) – First Liver-Directed Drug Approved for MASH

• Mechanism: Selective thyroid hormone receptor-beta (THR-β) agonist
  • THR-β is highly expressed in liver (not heart), regulating lipid metabolism
  • Reduces hepatic lipogenesis and increases fatty acid oxidation
  • Lowers LDL cholesterol and triglycerides
• Evidence:
  • "MAESTRO-NASH trial (2024): Phase 3 RCT in 966 patients with biopsy-proven MASH and F2-F3 fibrosis"
    • MASH resolution without worsening fibrosis: 26% (80 mg), 30% (100 mg) vs 10% (placebo)
    • Fibrosis improvement without worsening MASH: 24% (80 mg), 26% (100 mg) vs 14% (placebo)
    • Significant reductions in LDL-C, triglycerides, liver fat content [23]
• Dose: 80-100 mg once daily
• Approval: FDA approved March 2024 for MASH with moderate-to-advanced fibrosis (F2-F3); NICE/EMA approval pending
• Limitations:
  • Long-term safety data still accumulating
  • Expensive
  • Diarrhoea (most common side effect, generally mild)
  • Requires biopsy-proven MASH for eligibility (currently)

B. Agents Targeting Metabolic Comorbidities (with Hepatic Benefits)

1. GLP-1 Receptor Agonists

• Mechanism: Incretin mimetics; enhance glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, reduce appetite
• Evidence:
  • "LEAN trial (Liraglutide): 1.8 mg daily for 48 weeks resulted in MASH resolution in 39% vs 9% placebo in diabetic patients [24]"
  • "Semaglutide: 2.4 mg weekly showed greater weight loss and greater reduction in hepatic steatosis and fibrosis markers than placebo (ongoing Phase 3 trials)"
• Indications: Type 2 diabetes with MASLD/MASH; obesity with MASLD
• Advantages:
  • Substantial weight loss (5-15% depending on agent/dose)
  • Cardiovascular benefits (reduced MACE in dedicated CV outcomes trials)
  • Improving glycaemic control
• Limitations:
  • Gastrointestinal side effects (nausea, vomiting, diarrhoea)
  • Expensive
  • Injectable
• Guideline status: Recommended for diabetic patients with MASLD; increasingly used for obesity management

2. SGLT-2 Inhibitors

• Mechanism: Sodium-glucose cotransporter-2 inhibition in kidney; promotes glycosuria, weight loss, reduces insulin resistance
• Evidence: Observational and small RCTs suggest reduction in liver fat and transaminases; large histological outcome trials ongoing
• Advantages: Cardiovascular and renal protection in diabetes; weight loss
• Guideline status: Reasonable choice for diabetic patients with MASLD; insufficient evidence for primary MASH indication

3. Statins

• Indication: Cardiovascular disease prevention (MASLD patients have high CVD risk)
• Safety: Statins are SAFE in MASLD and MASH, including compensated cirrhosis [25]
  • Baseline ALT elevation is NOT a contraindication
  • Risk of hepatotoxicity is extremely low (less than 1%)
  • Monitor LFTs at baseline and 12 weeks, then annually
• Hepatic effects: May modestly reduce steatosis and fibrosis progression (secondary benefits)
• Guideline recommendation: Do NOT withhold statins in MASLD; actively treat dyslipidaemia and calculate 10-year CVD risk

C. Bariatric Surgery

Indications:

• BMI ≥40 kg/m²
• BMI ≥35 kg/m² with obesity-related comorbidities (including MASLD/MASH)

Evidence:

• Most effective intervention for sustained weight loss (25-35% total body weight loss)
• MASH resolution rates: 70-85%
• Fibrosis regression: 30-40% in follow-up studies
• Meta-analyses show significant improvement in all histological parameters [26]

Types:

• Roux-en-Y gastric bypass (RYGB): More weight loss, higher metabolic benefits, slightly higher complication rate
• Sleeve gastrectomy: Slightly less weight loss, lower complication rate, increasingly preferred

Considerations:

• Surgical risks increase with advanced liver disease (MELD score > 15 is relative contraindication)
• Improved cardiovascular outcomes and diabetes remission
• Requires lifelong nutritional monitoring (B12, iron, calcium, vitamin D)

Guideline status: AASLD supports bariatric surgery in appropriate candidates with MASLD/MASH

D. Agents NOT Recommended

• Ursodeoxycholic acid (UDCA): No benefit demonstrated in MASLD
• Metformin: Does NOT improve liver histology despite improving insulin sensitivity; used for diabetes management, not liver-directed
• Omega-3 fatty acids: May reduce liver fat but no histological benefit on inflammation or fibrosis

Management by Fibrosis Stage

Exam Detail: ### Special Populations

Pregnancy:

• MASLD/MASH is not a contraindication to pregnancy
• Discontinue potentially teratogenic agents (statins, pioglitazone, Vitamin E)
• Monitor liver function during pregnancy
• Distinguish from Acute Fatty Liver of Pregnancy (AFLP), a life-threatening third-trimester condition requiring urgent delivery

Paediatric MASLD:

• Lifestyle modification is first-line
• Pharmacotherapy generally avoided; Vitamin E may be considered in adolescents with biopsy-proven MASH
• Screen for genetic lipodystrophies and metabolic disorders

Chronic Kidney Disease (CKD):

• Metformin: Caution/contraindicate if eGFR less than 30 mL/min
• SGLT-2 inhibitors: Less effective if eGFR less than 30 mL/min
• Pioglitazone: Dose reduction not required, but monitor fluid status

Post-Liver Transplant:

• MASLD can recur in allograft (20-40% at 5 years)
• Metabolic syndrome management is critical
• Immunosuppression (especially corticosteroids, tacrolimus) worsens metabolic parameters

---

9. Complications

Hepatic Complications

1. Progressive Fibrosis and Cirrhosis

• 10-20% of MASH patients progress to cirrhosis over 10-20 years [4]
• Once cirrhosis develops, annual risk of decompensation is 2-4%
• Bridging fibrosis (F3) carries intermediate risk

2. Decompensated Cirrhosis

• Ascites (most common first decompensation event)
• Variceal haemorrhage (oesophageal or gastric varices)
• Hepatic encephalopathy
• Spontaneous bacterial peritonitis
• Hepatorenal syndrome
• Median survival after first decompensation: 2-3 years without transplantation

3. Hepatocellular Carcinoma (HCC)

• Annual incidence in MASLD cirrhosis: 1-3% [16]
• Unique to MASLD: HCC can develop in NON-cirrhotic livers with MASH (10-20% of MASLD-HCC occurs without cirrhosis) [16]
  • This complicates surveillance strategies, as standard guidelines recommend surveillance only in cirrhosis
• Risk factors for HCC: Cirrhosis, older age, diabetes, obesity, Hispanic ethnicity, PNPLA3 I148M variant

4. Acute-on-Chronic Liver Failure (ACLF)

• Precipitated by infection, alcohol, drugs, GI bleeding, or surgery in advanced MASLD
• High short-term mortality (30-50%)

Extrahepatic Complications

1. Cardiovascular Disease – Leading Cause of Death in MASLD [5]

• Increased risk of coronary artery disease, myocardial infarction, stroke
• MASLD is an independent risk factor for CVD beyond traditional metabolic syndrome components
• Pathophysiology: Shared metabolic pathways, systemic inflammation, atherogenic dyslipidaemia, insulin resistance

2. Type 2 Diabetes Mellitus

• Bidirectional relationship: MASLD increases diabetes risk, and diabetes worsens MASLD
• MASLD patients have 2-3× increased risk of incident diabetes

3. Chronic Kidney Disease (CKD)

• MASLD independently associated with CKD incidence and progression
• Shared metabolic risk factors
• Monitor eGFR and urinary albumin-to-creatinine ratio annually

4. Obstructive Sleep Apnoea (OSA)

• High prevalence in MASLD (30-50%)
• OSA worsens insulin resistance and hepatic inflammation via intermittent hypoxia
• Screen with questionnaires (STOP-BANG, Epworth Sleepiness Scale); refer for sleep study if positive
• CPAP treatment may improve liver outcomes

5. Extrahepatic Malignancies

• Increased risk of colorectal cancer (consider earlier/more frequent screening) [27]
• Possible associations with pancreatic, breast, gastric, and oesophageal cancers

6. Polycystic Ovary Syndrome (PCOS)

• Common comorbidity in women with MASLD
• Shared pathophysiology of insulin resistance

---

10. Prognosis and Outcomes

Natural History

Simple Steatosis (MASL):

• Benign course in majority (70-80%)
• Liver-related mortality similar to general population
• Annual progression to MASH: 1-2%
• Cardiovascular disease is main cause of death

MASH:

• More aggressive course
• 20-30% progress to advanced fibrosis (F3-F4) over 10-20 years
• 10-20% develop cirrhosis
• Increased liver-related and all-cause mortality

MASH Cirrhosis:

• Annual decompensation rate: 2-4%
• Annual HCC incidence: 1-3%
• Median survival without transplantation after decompensation: 2-3 years
• Liver transplantation improves survival but recurrence in allograft is common

Prognostic Factors

Most Important: Fibrosis Stage [7]

• F0-F1: No increased liver-related mortality
• F2: Mild increase in liver events; intermediate risk
• F3: Significantly increased liver-related and all-cause mortality
• F4: High risk; requires specialist management and surveillance

Other Factors Associated with Worse Outcomes:

• Older age at diagnosis
• Type 2 diabetes
• Obesity (especially BMI > 35 kg/m²)
• PNPLA3 I148M homozygosity
• Elevated AST/ALT ratio > 1 (suggests advanced disease)
• Low platelet count
• Elevated ferritin

Protective Factors:

• Weight loss ≥7-10%
• Coffee consumption
• Mediterranean diet adherence
• Good glycaemic and blood pressure control
• Statin use

Mortality

Causes of Death in MASLD Patients (in order of frequency) [5]:

1. Cardiovascular disease (40-50%): Myocardial infarction, stroke, heart failure
2. Malignancy (25-30%): HCC, extrahepatic cancers (colorectal, lung, breast)
3. Liver-related (15-20%): Decompensation, HCC, variceal bleeding
4. Other (10-15%): Infection, renal failure, diabetes complications

Overall Mortality:

• MASLD patients without fibrosis: Similar to general population
• MASLD with F3-F4 fibrosis: Hazard ratio 3-4× for liver-related death; 1.5-2× for all-cause death

Reversibility

Good News: Fibrosis is potentially reversible, even at advanced stages (F3), with aggressive metabolic intervention. [19]

• Weight loss ≥10%: Fibrosis regression in ~45%
• Bariatric surgery: Fibrosis improvement in 30-40%
• Resmetirom: Fibrosis improvement in 24-26%
• Pioglitazone: Fibrosis improvement in meta-analyses

Cirrhosis (F4): Less reversible, but metabolic control can prevent decompensation and possibly reduce HCC risk.

---

11. Prevention and Screening

Primary Prevention

Population-Level Interventions:

• Public health campaigns targeting obesity, physical inactivity, and unhealthy diets
• Taxation of sugar-sweetened beverages
• Improved food labelling
• Urban planning to encourage active transport

Individual-Level Prevention:

• Maintain healthy weight (BMI 18.5-24.9 kg/m², or 18.5-22.9 for Asians)
• Regular physical activity (150 minutes/week moderate-intensity)
• Mediterranean diet pattern
• Limit alcohol consumption
• Avoid unnecessary medications

Secondary Prevention (Screening for MASLD)

Who to Screen: Major societies (AASLD, EASL) do NOT recommend universal population screening due to:

• High prevalence (would overwhelm services)
• Lack of licensed pharmacotherapy for non-cirrhotic MASLD
• Uncertainty about cost-effectiveness

Recommended Targeted Case-Finding: Screen high-risk populations with metabolic risk factors:

Screening Tests:

1. Liver function tests (ALT, AST, GGT, ALP, bilirubin, albumin, INR)
2. Metabolic panel (fasting glucose or HbA1c, lipid profile)
3. FIB-4 score (if MASLD suspected or confirmed)
4. Liver ultrasound (if LFTs abnormal or high clinical suspicion)

Follow-Up After Screening:

• FIB-4 less than 1.30: Reassure, lifestyle advice, annual monitoring
• FIB-4 ≥1.30: Second-line test (ELF or FibroScan); consider hepatology referral
• FIB-4 > 2.67 or FibroScan ≥8 kPa: Refer to hepatology

Tertiary Prevention (Preventing Progression)

In patients with established MASLD:

• Aggressive metabolic risk factor control
• Target weight loss 7-10%
• Treat diabetes, hypertension, dyslipidaemia to target
• Avoid alcohol
• Regular monitoring of fibrosis progression (annual FIB-4, repeat FibroScan every 1-2 years)
• HCC surveillance in cirrhosis (ultrasound + AFP every 6 months)
• Variceal screening in cirrhosis (endoscopy at diagnosis, then every 1-3 years)

---

12. Key Guidelines

---

13. Examination Focus

Common Exam Questions

1. "What are the diagnostic criteria for MASLD?"

• Hepatic steatosis (> 5% on imaging or histology) AND
• At least one of five cardiometabolic risk factors (obesity, dysglycaemia, hypertension, dyslipidaemia – see Section 1)
• Absence of significant alcohol intake (less than 20 g/day women, less than 30 g/day men)
• Exclusion of other causes of steatosis (viral hepatitis, medications, Wilson's disease, etc.)

2. "How do you risk-stratify a patient with MASLD?"

• Calculate FIB-4 score (Age × AST / [Platelets × √ALT])
• FIB-4 less than 1.30: Low risk, primary care management
• FIB-4 ≥1.30: Indeterminate/high risk, requires second-line test (ELF blood test or FibroScan)
• If ELF ≥9.8 or FibroScan ≥8 kPa: High risk of advanced fibrosis, refer to hepatology

3. "What is the most important prognostic factor in MASLD?"

• Fibrosis stage is the single most important determinant of liver-related and all-cause mortality
• Patients with F0-F2 have similar mortality to general population
• F3-F4 confers significantly increased risk

4. "What is the first-line treatment for MASLD?"

• Lifestyle modification with weight loss:
  • Target 7-10% weight reduction
  • Mediterranean diet
  • 150 minutes/week moderate-intensity exercise
• No pharmacotherapy is currently first-line; resmetirom is FDA-approved for MASH with F2-F3 (2024) but not yet widely available
• Treat metabolic comorbidities (diabetes, hypertension, dyslipidaemia) aggressively
• Statins are safe and should be used for cardiovascular risk reduction

5. "What is the leading cause of death in MASLD patients?"

• Cardiovascular disease (MI, stroke), not liver-related causes
• Management must prioritise CVD risk reduction

6. "Can HCC develop in MASLD without cirrhosis?"

• Yes, unique to MASLD (and HBV); 10-20% of MASLD-related HCC occurs in non-cirrhotic livers
• Complicates surveillance, as current guidelines recommend HCC screening only in cirrhosis

7. "What is the difference between MASLD and NAFLD?"

• Nomenclature updated in 2023: NAFLD → MASLD; NASH → MASH
• Rationale: Remove stigma of "fatty" and "non-alcoholic"; emphasise positive metabolic criteria
• Diagnostic criteria now require cardiometabolic risk factors, not just absence of alcohol

8. "What are the components of the NAS score?"

• NAFLD Activity Score (NAS): Steatosis (0-3) + Lobular Inflammation (0-3) + Ballooning (0-2)
• Total 0-8; ≥5 suggests MASH, but NAS is not diagnostic in isolation (requires categorical assessment of MASH features)

Viva Points

Viva Point: Opening statement: "MASLD, or Metabolic Dysfunction-Associated Steatotic Liver Disease, is the hepatic manifestation of metabolic syndrome, affecting approximately 25-30% of the global population. It ranges from simple steatosis to MASH, which can progress to cirrhosis and hepatocellular carcinoma. The key pathophysiological driver is insulin resistance, and the most important prognostic factor is the degree of hepatic fibrosis."

Key facts to mention:

• Prevalence: 25-30% globally; 55-70% in type 2 diabetes; 70-90% in obesity [3,8,9]
• Nomenclature: Updated from NAFLD/NASH to MASLD/MASH in 2023 [1]
• Diagnosis: Steatosis + ≥1 cardiometabolic risk factor; exclude alcohol and secondary causes
• Fibrosis risk stratification: FIB-4 score first-line (using age, AST, ALT, platelets); less than 1.30 low risk, ≥1.30 requires second-line test (ELF or FibroScan)
• Management: Weight loss 7-10% is cornerstone (reverses MASH and fibrosis); treat metabolic comorbidities; statins are safe; resmetirom FDA-approved 2024 for MASH with F2-F3
• Prognosis: Fibrosis stage determines outcome; cardiovascular disease is leading cause of death, not liver failure [5,7]
• Complications: 10-20% of MASH progresses to cirrhosis; 1-3% annual HCC risk in cirrhosis; HCC can occur without cirrhosis in MASLD [4,16]

Common Mistakes

❌ Mistake 1: Assuming normal ALT excludes significant disease

• Correction: 50% of patients with advanced fibrosis have normal transaminases; FIB-4 screening is needed even if LFTs normal in high-risk groups [6]

❌ Mistake 2: Withholding statins due to elevated ALT or concerns about "liver disease"

• Correction: Statins are safe in MASLD, including compensated cirrhosis, and reduce cardiovascular mortality (the main cause of death); monitor LFTs but do not withhold [25]

❌ Mistake 3: Confusing FIB-4 with NAFLD Fibrosis Score (NFS)

• Correction: FIB-4 uses age, AST, ALT, platelets. NFS uses age, BMI, diabetes, albumin, AST/ALT ratio. FIB-4 is simpler and preferred first-line in most guidelines.

❌ Mistake 4: Believing ultrasound or CAP can diagnose MASH

• Correction: Imaging detects steatosis only. MASH is a histological diagnosis (requires inflammation + ballooning), which can only be confirmed by liver biopsy or inferred by biomarkers/elastography in research contexts.

❌ Mistake 5: Recommending alcohol abstinence is unnecessary in "non-alcoholic" fatty liver

• Correction: Despite the name, alcohol (even moderate amounts) synergistically worsens liver injury in MASLD; advise abstinence or minimal intake.

❌ Mistake 6: Thinking metformin treats MASLD

• Correction: Metformin improves insulin sensitivity and treats diabetes but does NOT improve liver histology; it is not a liver-directed therapy.

Model Answers

Q: Describe your approach to a 52-year-old obese man with type 2 diabetes found to have fatty liver on ultrasound.

Model Answer:

"I would approach this systematically, recognising this patient is at high risk for MASLD given his obesity and diabetes.

First, I would confirm the diagnosis:

• Take a detailed history, including alcohol intake (must be less than 30 g/day to meet MASLD criteria), medications, and family history
• Examine for stigmata of chronic liver disease and metabolic syndrome (acanthosis nigricans, hepatomegaly, signs of cirrhosis)
• Perform a 'liver screen' to exclude secondary causes: hepatitis B and C serology, autoimmune markers (ANA, ASMA, immunoglobulins), iron studies (ferritin, transferrin saturation), and coeliac serology; I would also check thyroid function and ensure he has had diabetes screening

Second, I would assess his cardiometabolic risk factors:

• This patient already has two criteria (obesity and diabetes), so MASLD is confirmed by definition
• I would also assess for hypertension and dyslipidaemia (lipid profile)

Third, and critically, I would risk-stratify for fibrosis, as this determines prognosis and management intensity:

• Calculate FIB-4 score using his age, AST, ALT, and platelet count
• If FIB-4 less than 1.30, he is low risk and can be managed in primary care with lifestyle modification and annual monitoring
• If FIB-4 ≥1.30, he requires second-line assessment with Enhanced Liver Fibrosis (ELF) blood test or transient elastography (FibroScan)
• If ELF ≥9.8 or liver stiffness ≥8 kPa, he has probable advanced fibrosis and requires hepatology referral

Fourth, I would address cardiovascular risk, which is the leading cause of death in MASLD:

• Calculate 10-year cardiovascular risk
• Initiate or optimise statin therapy (statins are safe in MASLD and reduce mortality)
• Ensure blood pressure is controlled to target
• Consider antiplatelet therapy if indicated

Fifth, I would initiate lifestyle modification:

• Target 7-10% weight loss over 6-12 months (this is the only intervention proven to reverse fibrosis)
• Recommend Mediterranean diet, reduction in fructose and processed foods
• Encourage 150 minutes per week of moderate-intensity exercise
• Advise alcohol reduction or abstinence

Finally, I would optimise his diabetes control:

• Consider GLP-1 receptor agonist (e.g., semaglutide) as this promotes weight loss and has shown benefit in MASH resolution in the LEAN trial
• If he has biopsy-proven MASH, I might consider pioglitazone (improves histology in diabetics, though weight gain is a side effect)

Ongoing monitoring: Annual FIB-4, LFTs every 6-12 months, and repeat FibroScan if abnormal at baseline. If he develops cirrhosis (F4), he would need HCC surveillance (ultrasound and AFP every 6 months) and variceal screening (endoscopy)."

---

14. Patient and Layperson Explanation

What is MASLD?

MASLD stands for Metabolic Dysfunction-Associated Steatotic Liver Disease. It used to be called "fatty liver disease" or NAFLD. It means your liver has too much fat stored inside its cells – more than 5% of the liver is fat when it should normally be almost none.

The fat builds up because of problems with how your body handles sugar and fat in your diet, often linked to being overweight, having diabetes, high blood pressure, or high cholesterol. Think of it as the liver version of metabolic syndrome.

Is it caused by alcohol?

No. This is a different condition from alcohol-related liver disease. However, drinking alcohol on top of MASLD makes things worse, so doctors usually recommend cutting down or stopping alcohol altogether, even though it's not the original cause.

Is it serious?

For most people (about 80%), the fat just sits in the liver and doesn't cause any problems – this is called simple steatosis. You can live a normal, healthy life with it.

However, for about 20-30%, the fat irritates the liver and causes inflammation, like a low-grade burn. This is called MASH (Metabolic Dysfunction-Associated Steatohepatitis). Over 10-20 years, MASH can cause scarring in the liver (called fibrosis). If the scarring becomes severe, it's called cirrhosis, and the liver can stop working properly.

The good news is that the liver is very good at healing itself if you make healthy changes.

What are the symptoms?

Most people have no symptoms at all. The condition is usually found by accident when you have a blood test or an ultrasound scan for something else.

Some people feel tired or have a mild ache on the right side of their tummy (where the liver sits), but these symptoms are not specific to liver disease.

If the disease becomes very advanced (cirrhosis), you might notice swelling in your belly or legs, yellowing of your skin or eyes (jaundice), or confusion. These are signs that you need urgent medical help.

Can it be cured?

There is no quick fix or magic pill, but the liver can heal itself if you lose weight and improve your health.

Research shows that:

• Losing 7-10% of your body weight can reverse the inflammation (MASH)
• Losing 10% or more can even reverse the scarring (fibrosis) in nearly half of people

The best treatments are:

1. Weight loss: Through a healthy diet (Mediterranean-style: lots of vegetables, fish, olive oil; less sugar and processed food) and regular exercise (150 minutes per week, like brisk walking)
2. Managing diabetes, blood pressure, and cholesterol with medication if needed
3. Avoiding or minimising alcohol

For people with more severe disease, there are medications (like pioglitazone for diabetes, or a new drug called resmetirom) and, in very severe obesity, weight-loss surgery can be very effective.

What's the biggest risk?

Interestingly, the liver is not usually the biggest problem. Most people with MASLD die from heart attacks and strokes, not liver failure. That's why controlling your blood pressure, cholesterol, and blood sugar is so important – it protects your heart as well as your liver.

What should I do?

1. Follow up with your doctor to get your liver checked (blood tests and possibly a scan)
2. Lose weight gradually (even 5% helps) through diet and exercise
3. Take medications as prescribed for diabetes, blood pressure, and cholesterol
4. Cut down or stop alcohol
5. Get regular check-ups to monitor your liver

The earlier you make these changes, the better your liver (and heart) will do in the long run.

---

15. References

Primary Sources

1. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. doi:10.1016/j.jhep.2023.06.003

2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi:10.1016/j.jhep.2015.11.004

3. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431

4. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-654. doi:10.1016/j.cgh.2014.04.014

5. Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. doi:10.1016/j.jhep.2016.05.013

6. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286-1292. doi:10.1053/jhep.2003.50229

7. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557-1565. doi:10.1002/hep.29085

8. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801. doi:10.1016/j.jhep.2019.06.021

9. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112-117. doi:10.7326/0003-4819-132-2-200001180-00004

10. Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92(9):3490-3497. doi:10.1210/jc.2007-0482

11. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739-752. doi:10.1016/S2468-1253(20)30077-7

12. Anderson EL, Howe LD, Jones HE, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0140908. doi:10.1371/journal.pone.0140908

13. Ballestri S, Nascimbeni F, Baldelli E, et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34(6):1291-1326. doi:10.1007/s12325-017-0556-1

14. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-1465. doi:10.1038/ng.257

15. McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148-1155. doi:10.1016/j.jhep.2014.11.034

16. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828-1837. doi:10.1053/j.gastro.2018.08.024

17. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-231. doi:10.1016/j.jhep.2005.10.013

18. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351. doi:10.1172/JCI23621

19. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378. doi:10.1053/j.gastro.2015.04.005

20. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-846. doi:10.1016/j.jhep.2017.05.016

21. Ding M, Bhupathiraju SN, Chen M, et al. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care. 2014;37(2):569-586. doi:10.2337/dc13-1203

22. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS trial). N Engl J Med. 2010;362(18):1675-1685. doi:10.1056/NEJMoa0907929

23. Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000

24. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. doi:10.1016/S0140-6736(15)00803-X

25. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916-1922. doi:10.1016/S0140-6736(10)61272-X

26. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159(4):1290-1301. doi:10.1053/j.gastro.2020.06.006

27. Wong VW, Wong GL, Tsang SW, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60(6):829-836. doi:10.1136/gut.2011.237974

28. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323

29. National Institute for Health and Care Excellence (NICE). Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline [NG49]. Published July 2016. Updated 2024. https://www.nice.org.uk/guidance/ng49

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines.